The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.
 
Karyn A. Goodman
Consulting or Advisory Role - Novartis; Philips Healthcare; RenovoRx; Roche/Genentech
 
Rui-hua Xu
No Relationships to Disclose
 
Ian Chau
Honoraria - Eisai; Lilly; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Pierre Fabre; Roche/Genentech; Sotio
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD
 
Ming Huang Chen
No Relationships to Disclose
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; Janssen; Joseah Biopharma; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Manish A. Shah
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical
 
Yifan Wang
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Mari Ichimaru
Employment - Genentech; Merck
Stock and Other Ownership Interests - Genentech
 
Qingyuan Liu
Employment - Roche
 
Luhua Wang
Employment - Cancer Hospital Chinese Academy of Medical Sciences
Leadership - Cancer Hospital Chinese Academy of Medical Sciences
Honoraria - Roche